BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)‘s stock had its “buy” rating reissued by BMO Capital Markets in a research report issued on Friday. They currently have a $117.00 price target on the biotechnology company’s stock. BMO Capital Markets’ price target would indicate a potential upside of 33.33% from the company’s previous close.

BMRN has been the subject of several other research reports. Morgan Stanley reaffirmed an “overweight” rating and issued a $117.00 price target (up previously from $115.00) on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $129.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $119.00 price target (up previously from $118.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, August 3rd. Royal Bank Of Canada began coverage on shares of BioMarin Pharmaceutical in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $93.00 price target for the company. Finally, Zacks Investment Research raised shares of BioMarin Pharmaceutical from a “hold” rating to a “strong-buy” rating and set a $105.00 price target for the company in a research report on Monday, July 17th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $111.25.

Shares of BioMarin Pharmaceutical (NASDAQ BMRN) traded down 0.43% during mid-day trading on Friday, reaching $87.75. 1,329,196 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $92.57 and a 200 day moving average price of $90.05. BioMarin Pharmaceutical has a 12-month low of $78.42 and a 12-month high of $100.51. The firm’s market capitalization is $15.38 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. The business had revenue of $317.50 million for the quarter, compared to the consensus estimate of $311.41 million. BioMarin Pharmaceutical had a negative net margin of 15.54% and a negative return on equity of 5.77%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.61) EPS. Analysts anticipate that BioMarin Pharmaceutical will post ($0.73) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/20/biomarin-pharmaceutical-inc-bmrn-receives-buy-rating-from-bmo-capital-markets.html.

In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 15,000 shares of the stock in a transaction on Friday, September 15th. The shares were sold at an average price of $90.50, for a total transaction of $1,357,500.00. Following the transaction, the insider now directly owns 141,422 shares of the company’s stock, valued at $12,798,691. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director V Bryan Lawlis sold 3,750 shares of the stock in a transaction on Friday, September 15th. The shares were sold at an average price of $91.26, for a total transaction of $342,225.00. Following the transaction, the director now directly owns 19,660 shares in the company, valued at $1,794,171.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,686 shares of company stock worth $3,736,318. Insiders own 1.85% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of BMRN. Cigna Investments Inc. New lifted its stake in shares of BioMarin Pharmaceutical by 1.5% in the second quarter. Cigna Investments Inc. New now owns 2,377 shares of the biotechnology company’s stock worth $216,000 after buying an additional 36 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of BioMarin Pharmaceutical by 1.0% in the second quarter. Daiwa Securities Group Inc. now owns 4,950 shares of the biotechnology company’s stock worth $450,000 after buying an additional 50 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of BioMarin Pharmaceutical by 1.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,126 shares of the biotechnology company’s stock worth $284,000 after buying an additional 54 shares in the last quarter. NGAM Advisors L.P. lifted its stake in shares of BioMarin Pharmaceutical by 0.4% in the second quarter. NGAM Advisors L.P. now owns 15,245 shares of the biotechnology company’s stock worth $1,385,000 after buying an additional 55 shares in the last quarter. Finally, First American Trust FSB lifted its stake in shares of BioMarin Pharmaceutical by 0.3% in the second quarter. First American Trust FSB now owns 26,696 shares of the biotechnology company’s stock worth $2,424,000 after buying an additional 73 shares in the last quarter. 97.29% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.